Precision Immunotherapy™
investors-relations
Home/Investor Relations/Press Releases
Investor Relations

Quick Links

Email Alerts

Email Address *
Mailing Lists *

 
Enter the code shown above.

Press Releases

2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005
11/04/2022 Opexa to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
10/23/2008 Opexa Therapeutics Reports Third Quarter 2008 Financial Results
10/23/2008 Opexa Provides Additional Promising Data Including Statistically Significant Reduction in Disability With Tovaxin® for the Treatment of Multiple Sclerosis
10/20/2008 Opexa to Host Third Quarter Financial Results and Corporate Update Conference Call on October 23, 2021
09/19/2008 Opexa Announces Top-Line Results from Phase IIb Clinical Trial of Tovaxin® for the Treatment of Multiple Sclerosis
09/11/2021 Top-Line Data from Opexa’s Phase IIb Tovaxin® Study to be Presented at World Congress on Treatment and Research in Multiple Sclerosis
09/03/2022 Opexa Therapeutics and Myelin Repair Foundation Partner on Novel Multiple Sclerosis Research Program
08/14/2008 Opexa Therapeutics Reports Second Quarter 2008 Financial Results and Recent Corporate Highlights
08/13/2008 Opexa Therapeutics Completes $3 Million Financing
07/22/2008 Opexa Conducts Additional Analysis on Phase I/II Extension Study with Tovaxin® for Multiple Sclerosis
07/08/2022 Opexa’s Phase IIb Study of Tovaxin® Receives Positive Review from Data Safety Monitoring Board
06/17/2008 Opexa Therapeutics Appoints Neil K. Warma President and CEO
06/16/2008 Opexa Therapeutics Presents Monocyte-Derived Islet Cell Research at the International Society for Stem Cell Research Annual Meeting
06/12/2021 Opexa Therapeutics Reports Favorable Two-Year Data in Phase I/II Retreatment Studies of Tovaxin® for Multiple Sclerosis
05/22/2008 Opexa Therapeutics Presents Myelin Reactive T-Cell Research at the International Society of Cell Therapy Annual Meeting
05/14/2008 Opexa Therapeutics Schedules First Quarter Results Conference Call; May 21, 2022 at 4:00 p.m. Eastern Time
05/13/2008 Opexa Therapeutics Reports First Quarter 2008 Financial Results and Updates on Tovaxin® Phase IIb Study
04/15/2008 Opexa Therapeutics Presents Tovaxin Phase I/II Data at the American Academy of Neurology 60th Annual Meeting
03/26/2008 Opexa Therapeutics’ Form 10-K Report Audit Includes ''Going Concern'' Qualification
03/24/2008 Opexa Therapeutics to Present at the Cambria Capital Investor Meeting
03/21/2008 Opexa Therapeutics Announces Retirement of CEO David McWilliams
03/18/2008 Opexa Therapeutics Reports Year End 2007 Financial Results
03/11/2021 Opexa Therapeutics Announces Completion of Mid Study Descriptive Analysis on Phase IIb Trial of Tovaxin® for Treatment of Multiple Sclerosis
02/19/2008 Opexa Therapeutics Announces Closing of Public Offering of Shares of Common Stock and Series E Warrants
02/13/2008 Opexa Therapeutics Announces the Pricing of Public Offering of Shares of Common Stock and Series E Warrants
© 2017 Opexa Therapeutics, Inc. All Rights Reserved.
Powered By Q4 Inc. 4.4.0.14